Nordic Nanovector ASA - Stabilisation notice and exercise of over-allotment option, total gross proceeds from IPO increase to NOK 575 million

Nordic Nanovector ASA - Stabilisation notice and exercise of over-allotment option, total gross proceeds from IPO increase to NOK 575 million

Oslo, 22 April 2015: Reference is made to the announcement issued by Nordic Nanovector ASA ("Nordic Nanovector" or the "Company", ticker code "NANO") and ABG Sundal Collier Norge ASA (the "Stabilisation Manager") on 20 March 2015 regarding potential stabilisation activities in respect of the shares in Nordic Nanovector in the period from 23 March 2015 to and including 21 April 2015 (the "Stabilisation Period") in connection with Nordic Nanovector's initial public offering (the "Offering").

The Stabilisation Manager hereby gives notice that no stabilisation purchases have been undertaken in relation to the shares in Nordic Nanovector and that no further stabilisation activities will be carried out.The Stabilisation Manager has exercised the option to purchase from the Company 2,343,750 new shares in the Company (the "Over-Allotment Option"), equalling 15% of the aggregate number of new shares allocated in the Offering, at a price per share of NOK 32, which is equal to the offer price in the Offering. The 2,343,750 shares will be delivered to HealthCap VI L.P. from whom the same number of shares were borrowed in connection with the over-allotment and stabilisation activities in the Offering.

After the issuance of the shares in connection with the exercise of the Over-Allotment Option, the Company will have 44,519,041 shares in issue and will receive NOK 75 million in additional proceeds from the Offering and accordingly, total gross proceeds from the Offering increases to NOK 575 million.

For further queries, please contact:

ABG Sundal Collier Norge ASA
+47 22 01 60 00

About Nordic Nanovector
Nordic Nanovector is a biotech company focusing on the development and commercialization of novel targeted therapeutics in haematology and oncology. The Company's lead clinical-stage product opportunity is Betalutin™, the first in a new class of Antibody-Radio-Conjugates (ARCs), designed to improve upon and complement current options for the treatment of Non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin™ comprises a tumor-seeking anti-CD37 antibody conjugated to low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population and as well as a very favourable tolerability. Betalutin™ is fast advancing through clinical development and with first approval anticipated in 2018.

Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialization of Betalutin™ in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat a number of select cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

IMPORTANT INFORMATION

United States
These materials may not be published, distributed or transmitted in the United States, Canada, Australia or Japan. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "Shares") of Nordic Nanovector ASA (the "Company") in the United States, Norway or any other jurisdiction. The Shares of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The Shares of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act.

European Economic Area
Any offering of securities will be made by means of a prospectus to be published that may be obtained from the issuer or selling security holder, once published, and that will contain detailed information about the Company and its management, as well as financial statements.

These materials are an advertisement and not a prospectus for the purposes of Directive 2003/71/EC, as amended (together with any applicable implementing measures in any Member State, the "Prospectus Directive"). Investors should not subscribe for any securities referred to in these materials except on the basis of information contained in the prospectus.

In any EEA Member State other than Norway (from the time the prospectus has been approved by the Financial Supervisory Authority of Norway, in its capacity as the competent authority in Norway, and published in accordance with the Prospectus Directive as implemented in Norway) that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at "qualified investors" in that Member State within the meaning of Article 2(1)(e) of the Prospectus Directive ("Qualified Investors"), i.e., only to investors to whom an offer of securities may be made without the requirement for the Company to publish a prospectus pursuant to Article 3 of the Prospectus Directive in such EEA Member State.

United Kingdom
In the United Kingdom, these materials are only being distributed to and are only directed at Qualified Investors who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This information was brought to you by Cision http://news.cision.com

Contacts
ABG Sundal Collier Norge ASA
+47 22 01 60 00
 

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.